Synonyms: Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
tildrakizumab is an approved drug (EMA & FDA (2018))
Compound class:
Antibody
|
Immunopharmacology Comments |
Tildrakizumab inhibits IL-23 receptor signalling by sequestering free ligand. This action down modulates the release of pro-inflammatory cytokines and chemokines, and reduces disease pathology. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Psoriasis |
Disease Ontology:
DOID:8893 |
Approved drug for moderate to severe plaque psoriasis. | 3 |